Bullous Pemphigoid and Diabetes medications: A disproportionality analysis based on the FDA Adverse Event Reporting System

Background: The world's first Diabetes Medications (Insulin) was marketed in October 1923. Some studies suggested the association of diabetes medications with Bullous Pemphigoid (BP), especially the Dipeptidyl Peptidase 4 (DPP-4) inhibitors. The study aims to detect an association between diabe...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Liting, Liu, Ying, Li, Huijun, Huang, Weicun, Geng, Ruirui, Tang, Zaixiang, Jiang, Yiguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2021
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040401/
https://www.ncbi.nlm.nih.gov/pubmed/33850463
http://dx.doi.org/10.7150/ijms.55421

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8040401/
https://www.ncbi.nlm.nih.gov/pubmed/33850463
http://dx.doi.org/10.7150/ijms.55421

Ejemplares similares